Specificity and activity of tumor antigen-reactive TIL used for adoptive cell therapy
Patient no. . | T2 . | T2/irrelevant peptide, 1 μM . | T2/MART-1, 1 μM . | T2/MART-1, 10 μM . | 888mel (A2− MART-1+) . | 526mel (A2+ MART-1+) . | 624mel (A2+ MART-1+) . | 2098mel (A2+ MART-1−) . | VβTCR of antigen-reactive clones . |
---|---|---|---|---|---|---|---|---|---|
9 | 59 | 92 | 5216† | ND | 5 | 4898† | 4794† | ND | Vβ12 |
10 | 10 | 36* | ND | 595† | 12 | 5580† | 4125† | ND | Vβ7 |
20 | 2 | 5 | 1165† | 2516† | 20 | 2061† | 1011† | 76 | ND |
21 | 30 | 17 | 15 | 19 | 12 | 25 | 21 | 1598† | Vβ22 |
23 | 23 | 22 | 1360† | 3040† | 17 | 1292† | 399† | 53 | Vβ14 |
28 | 3 | 7 | 2517† | 2872† | 20 | 2061† | 2148† | 167† | Vβ16 |
Patient no. . | T2 . | T2/irrelevant peptide, 1 μM . | T2/MART-1, 1 μM . | T2/MART-1, 10 μM . | 888mel (A2− MART-1+) . | 526mel (A2+ MART-1+) . | 624mel (A2+ MART-1+) . | 2098mel (A2+ MART-1−) . | VβTCR of antigen-reactive clones . |
---|---|---|---|---|---|---|---|---|---|
9 | 59 | 92 | 5216† | ND | 5 | 4898† | 4794† | ND | Vβ12 |
10 | 10 | 36* | ND | 595† | 12 | 5580† | 4125† | ND | Vβ7 |
20 | 2 | 5 | 1165† | 2516† | 20 | 2061† | 1011† | 76 | ND |
21 | 30 | 17 | 15 | 19 | 12 | 25 | 21 | 1598† | Vβ22 |
23 | 23 | 22 | 1360† | 3040† | 17 | 1292† | 399† | 53 | Vβ14 |
28 | 3 | 7 | 2517† | 2872† | 20 | 2061† | 2148† | 167† | Vβ16 |
Interferon-gamma secretion (pg/mL) from patient TIL stimulated with T2 cells pulsed with peptide at the indicated concentrations or with melanoma cell lines. Cytokine secretion from TIL was measured in multiple independent assays. Cryopreserved TIL were thawed and rested overnight in CM and rhIL-2 (50 cU/mL) prior to establishment of cocultures. T2 cells were pulsed with either MART-1:27-35 peptide or irrelevant peptide, gp 100:209-27.
ND indicates not determined; Vβ TCR, specific tumor antigen-reactive T-cell clones identified in TIL that persisted in the peripheral blood after adoptive transfer to lymphodepleted patients.
Control gp 100:280-288 peptide was used.
Values represent specific cytokine secretion specified as more than 3-fold increase compared with controls and more than 100 pg/mL concentration.